2. Apoptosis Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. Apoptosis COX Reactive Oxygen Species (ROS) Caspase SOD
  4. Macranthoidin B

Macranthoidin B  (Synonyms: Macranthoiside I)

Cat. No.: HY-N0864 Purity: 98.35%
COA
SDS
Handling Instructions Technical Support

Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels. Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma.

For research use only. We do not sell to patients.

Macranthoidin B

Macranthoidin B Chemical Structure

CAS No. : 136849-88-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Macranthoidin B:

Macranthoidin B Related Antibodies

Top Publications Citing Use of Products

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels. Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma[1][2][3].

In Vitro

Macranthoidin B (0-500 μM; 24 h) inhibits migration and invasion of primary endometriotic stromal cells and HEC1-B endometrial cancer cells, and suppresses epithelial-mesenchymal transition and the COX-2/PGE2 pathway[1].
Macranthoidin B (20-400 μM; 24-48 h) reduces the viability of HCT-116 colorectal cancer cells in a dose-dependent manner, induces cell apoptosis, and promotes ROS generation[2].
Macranthoidin B (20-400 μM; 48 h) dose-dependently promotes ROS production in HCT-116 colorectal cancer cells[2].
Macranthoidin B (20-400 μM; 48 h) dose-dependently downregulates the mRNA expression of antioxidant enzymes MnSOD and GSH-Px in HCT-116 colorectal cancer cells[2].
Macranthoidin B (100-400 μM; 24 h) inhibits the proliferation of Hepa1-6 cells in a dose-dependent manner and increases intracellular ROS levels[3].
Macranthoidin B (100-400 μM; 24 h) dose-dependently induces oxidative stress in Hepa1-6 cells, which is characterized by a significant increase in MDA levels and significant decreases in GSH levels, SOD activity and GSH-Px activity at all tested concentrations[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Macranthoidin B Related Antibodies

Cell Viability Assay[2]

Cell Line: HCT-116 colorectal cancer cells
Concentration: 20, 50, 100, 200, 400 μM
Incubation Time: 48 h
Result: Caused a dose-dependent decrease in cell viability, with significant reductions observed at all tested concentrations relative to control.

Western Blot Analysis[2]

Cell Line: HCT-116 colorectal cancer cells
Concentration: 20, 50, 100, 200, 400 μM
Incubation Time: 72 h
Result: Altered caspase-3 expression, increasing levels of cleaved caspase-3 in a dose-dependent manner.
In Vivo

Macranthoidin B (3-27 mg/kg; p.o.; daily; 28 days) inhibits the growth of ectopic lesions in a rat autotransplantation endometriosis model[1].
Macranthoidin B (16 mg/kg; i.p.; once daily; for 3 consecutive weeks) significantly inhibits the growth of colorectal cancer xenografts in nude mice by inducing tumor cell apoptosis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (SD) (female, 6-7 weeks old, 180-220 g, autograft implantation of endometrial segments endometriosis model)[1]
Dosage: 3 mg/kg; 9 mg/kg; 27 mg/kg
Administration: p.o.; daily; 28 days
Result: Reduced post-treatment ectopic endometrial volume compared to pretreatment.
Resulted in transplants with less adhesion and fewer surface blood vessels (9 and 27 mg/kg doses).
Improved pathological morphology of ectopic tissues, with fewer and smaller pseudo glands, reduced microvascularity, and decreased inflammatory cell infiltrations.
Decreased serum estradiol (E2) levels and increased serum progesterone (PROG) levels compared to the untreated endometriosis group.
Increased mRNA and protein expression of epithelial marker Cdh1/E-cadherin in ectopic tissues.
Decreased mRNA expression of mesenchymal markers Cdh2, Vim, Twist, Slug, Snail, Zeb1, and Zeb2, as well as protein expression of mesenchymal markers N-cadherin and Vimentin in ectopic tissues.
Reduced mRNA expression of Ptgs2 and Ptges, and decreased protein levels of COX-2 and PGE2 in ectopic tissues.
Animal Model: Nude mice (4 weeks old; half male, half female; engrafted with human HCT-116 colorectal cancer cells)[2]
Dosage: 16 mg/kg
Administration: i.p.; once daily; 3 weeks
Result: Reduced tumor volume significantly compared to vehicle control.
Reduced tumor weight significantly compared to vehicle control.
Increased TUNEL-positive cells per field significantly compared to vehicle control.
Elevated levels of cleaved caspase-3 compared to vehicle control.
Molecular Weight

1399.52

Formula

C65H106O32
CAS No.
Appearance

Solid

Color

White to light brown

SMILES

O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@@](OC[C@H](O)[C@@H]6O)([H])[C@@H]6O[C@@](O[C@@H](C)[C@H](O)[C@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O[C@]([C@@H]([C@@H](O)[C@@H]9O)O)([H])O[C@@H]9CO)O)([H])O[C@@H]8CO)([H])[C@@H]7O)[C@@]5(C)CO)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]%10O)O)O[C@@H]%10CO[C@@H]([C@@H]([C@@H](O)[C@@H]%11O)O)O[C@@H]%11CO
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (71.45 mM; Need ultrasonic)

DMSO : 100 mg/mL (71.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.7145 mL 3.5727 mL 7.1453 mL
5 mM 0.1429 mL 0.7145 mL 1.4291 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (1.79 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (1.79 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (71.45 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 0.7145 mL 3.5727 mL 7.1453 mL 17.8633 mL
5 mM 0.1429 mL 0.7145 mL 1.4291 mL 3.5727 mL
10 mM 0.0715 mL 0.3573 mL 0.7145 mL 1.7863 mL
15 mM 0.0476 mL 0.2382 mL 0.4764 mL 1.1909 mL
20 mM 0.0357 mL 0.1786 mL 0.3573 mL 0.8932 mL
25 mM 0.0286 mL 0.1429 mL 0.2858 mL 0.7145 mL
30 mM 0.0238 mL 0.1191 mL 0.2382 mL 0.5954 mL
40 mM 0.0179 mL 0.0893 mL 0.1786 mL 0.4466 mL
50 mM 0.0143 mL 0.0715 mL 0.1429 mL 0.3573 mL
60 mM 0.0119 mL 0.0595 mL 0.1191 mL 0.2977 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Macranthoidin B Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Macranthoidin B136849-88-2Macranthoiside IApoptosisCOXReactive Oxygen Species (ROS)CaspaseSODCyclooxygenaseSuperoxide DismutaseCOX-2/PGE2 pathwaythioredoxin reductasesendometriosisglutathione peroxidasesselenoproteinscolorectal cancerhepatocellular carcinomaprimary endometriotic stromal cellsdeiodinasesHEC1-B endometrial cancer cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Macranthoidin B
Cat. No.:
HY-N0864
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.